Aminoguanidine prolongs survival in azotemic-induced diabetic rats.
Toxic effects of hyperglycemia-induced advanced glycosylated end products (AGEs) may explain some vasculopathic complications of diabetes. Aminoguanidine, a known inhibitor of AGE formation, was administered by gavage to Sprague-Dawley streptozotocin-induced diabetic rats made azotemic by surgical reduction of renal mass. All rats became hyperglycemic. Renal ablation caused renal insufficiency, as evidenced by markedly reduced endogenous creatinine clearances at days 7 and 14. Aminoguanidine-treated rats had significantly (P < 0.04) superior survival to that of untreated azotemic diabetic rats. We infer from the extended life in a rat model of uremia in diabetic nephropathy that aminoguanidine may prove beneficial in human diabetes.
Friedman
E A
EA
Department of Medicine, State University of New York, Health Science Center at Brooklyn, 11203-2098, USA. elifreidmn@aol.com
Distant
D A
DA
Fleishhacker
J F
JF
Boyd
T A
TA
Cartwright
K
K
D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000150:complications* / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors*; D006146:Guanidines / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D014511:Uremia / Q000188:drug therapy* / Q000209:etiology
D004791:Enzyme Inhibitors; D017127:Glycation End Products, Advanced; D006146:Guanidines; C004479:pimagedine